The demo obtained each its Major endpoints, with semaglutide two.four mg demonstrating statistically major and exceptional improvements in liver fibrosis without worsening of steatohepatitis, in addition to resolution of steatohepatitis without any worsening of liver fibrosis in people with MASH when compared to placebo.1The subsequent really serio